HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Matrix metalloproteinase inhibitors.

Abstract
Matrix metalloproteinases (MMPs) are a family of zinc-dependent proteinases that are associated with the tumorigenic process. MMPs degrade the extracellular matrix, promoting tumor invasion and metastasis. They also regulate host defense mechanisms and normal cell function; blocking all MMPs may not lead to a positive therapeutic outcome. Most clinical trials of MMP inhibitors (MMPIs) have yielded disappointing results, perhaps due to inappropriate study design or tumor staging, or to lack of selectivity. Positive results have been seen in gastric cancer with marimastat and in Kaposi's sarcoma with metastat. This review summarizes the current status of MMPIs.
AuthorsNithya Ramnath, Patrick J Creaven
JournalCurrent oncology reports (Curr Oncol Rep) Vol. 6 Issue 2 Pg. 96-102 (Mar 2004) ISSN: 1523-3790 [Print] United States
PMID14751086 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Matrix Metalloproteinase Inhibitors
  • Protease Inhibitors
  • Matrix Metalloproteinases
Topics
  • Antineoplastic Agents (therapeutic use)
  • Clinical Trials as Topic
  • Enzyme Inhibitors (therapeutic use)
  • Humans
  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinases (genetics, metabolism)
  • Neoplasms (drug therapy, metabolism)
  • Protease Inhibitors (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: